These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
176 related items for PubMed ID: 9737371
1. Karyology and tumorigenicity testing requirements: past, present and future. Petricciani JC, Horaud FN. Dev Biol Stand; 1998; 93():5-13. PubMed ID: 9737371 [Abstract] [Full Text] [Related]
3. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials. EFSA GMO Panel Working Group on Animal Feeding Trials. Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408 [Abstract] [Full Text] [Related]
4. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Piver MS. Oncologist; 1996 Mar; 1(5):326-330. PubMed ID: 10388011 [Abstract] [Full Text] [Related]
5. Chromosomal characterization of MRC-5 cell banks utilizing G-banding technique. Rosolowsky M, McKee R, Nichols W, Garfinkle B. Dev Biol Stand; 1998 Mar; 93():109-17. PubMed ID: 9737385 [Abstract] [Full Text] [Related]
6. Production and control of live oral poliovirus vaccine in WI-38 human diploid cells. Stones PB. Dev Biol Stand; 1998 Mar; 37():251-3. PubMed ID: 1036401 [Abstract] [Full Text] [Related]
9. Cell substrates: where do we stand after 50 years of discussion? Petricciani J. Dev Biol (Basel); 2006 Mar; 123():11-21; discussion 55-73. PubMed ID: 16566432 [Abstract] [Full Text] [Related]
11. Cells, science and health. Petricciani JC. Dev Biol Stand; 1989 Mar; 70():3-10. PubMed ID: 2668074 [Abstract] [Full Text] [Related]
12. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1. Lunsford LD, Flickinger JC, Larson D. Oncologist; 1997 Mar; 2(1):59-61. PubMed ID: 10388030 [Abstract] [Full Text] [Related]
13. Physician Education: Myelodysplastic Syndrome. Yoshida Y. Oncologist; 1996 Mar; 1(4):284-287. PubMed ID: 10388004 [Abstract] [Full Text] [Related]
14. [Development of antituberculous drugs: current status and future prospects]. Tomioka H, Namba K. Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [Abstract] [Full Text] [Related]
19. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing. Thybaud V, Aardema M, Clements J, Dearfield K, Galloway S, Hayashi M, Jacobson-Kram D, Kirkland D, MacGregor JT, Marzin D, Ohyama W, Schuler M, Suzuki H, Zeiger E, Expert Working Group on Hazard Identification and Risk Assessment in Relation to In Vitro Testing. Mutat Res; 2007 Feb 03; 627(1):41-58. PubMed ID: 17126066 [Abstract] [Full Text] [Related]
20. Systematically experimental investigation on carcinogenesis or tumorigenicity of VERO cell lines of different karyotypes in nude mice in vivo used for viral vaccine manufacture. Zhang DL, Ji L, Li LJ, Huang GS. Yi Chuan Xue Bao; 2004 Jul 03; 31(7):647-60. PubMed ID: 15473315 [Abstract] [Full Text] [Related] Page: [Next] [New Search]